Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
MNTA's Cash to Debt is ranked higher than
99% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. MNTA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MNTA' s Cash to Debt Range Over the Past 10 Years
Min: 10.74  Med: 71.35 Max: No Debt
Current: No Debt
Equity to Asset 0.81
MNTA's Equity to Asset is ranked higher than
79% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MNTA: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
MNTA' s Equity to Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.86 Max: 0.96
Current: 0.81
-0.49
0.96
Interest Coverage No Debt
MNTA's Interest Coverage is ranked higher than
99% of the 475 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.69 vs. MNTA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MNTA' s Interest Coverage Range Over the Past 10 Years
Min: 110.84  Med: 10000.00 Max: 9999.99
Current: No Debt
110.84
9999.99
F-Score: 4
Z-Score: 4.63
M-Score: -1.35
WACC vs ROIC
15.75%
-428.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -86.10
MNTA's Operating margin (%) is ranked lower than
88% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.73 vs. MNTA: -86.10 )
Ranked among companies with meaningful Operating margin (%) only.
MNTA' s Operating margin (%) Range Over the Past 10 Years
Min: -448.33  Med: -249.62 Max: 63.48
Current: -86.1
-448.33
63.48
Net-margin (%) -84.65
MNTA's Net-margin (%) is ranked lower than
89% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.01 vs. MNTA: -84.65 )
Ranked among companies with meaningful Net-margin (%) only.
MNTA' s Net-margin (%) Range Over the Past 10 Years
Min: -429.9  Med: -247.20 Max: 63.71
Current: -84.65
-429.9
63.71
ROE (%) -24.44
MNTA's ROE (%) is ranked lower than
81% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.15 vs. MNTA: -24.44 )
Ranked among companies with meaningful ROE (%) only.
MNTA' s ROE (%) Range Over the Past 10 Years
Min: -66.11  Med: -32.35 Max: 59.21
Current: -24.44
-66.11
59.21
ROA (%) -21.17
MNTA's ROA (%) is ranked lower than
83% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. MNTA: -21.17 )
Ranked among companies with meaningful ROA (%) only.
MNTA' s ROA (%) Range Over the Past 10 Years
Min: -51.08  Med: -28.38 Max: 55.62
Current: -21.17
-51.08
55.62
ROC (Joel Greenblatt) (%) -357.44
MNTA's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.13 vs. MNTA: -357.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MNTA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -592.17  Med: -415.90 Max: 348.38
Current: -357.44
-592.17
348.38
Revenue Growth (3Y)(%) 3.80
MNTA's Revenue Growth (3Y)(%) is ranked lower than
57% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. MNTA: 3.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MNTA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.50 Max: 139.6
Current: 3.8
0
139.6
EBITDA Growth (3Y)(%) 5.70
MNTA's EBITDA Growth (3Y)(%) is ranked lower than
54% of the 553 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. MNTA: 5.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MNTA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.2  Med: -7.00 Max: 30.4
Current: 5.7
-45.2
30.4
EPS Growth (3Y)(%) 4.40
MNTA's EPS Growth (3Y)(%) is ranked lower than
55% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. MNTA: 4.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MNTA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.2  Med: -9.00 Max: 30.1
Current: 4.4
-48.2
30.1
» MNTA's 10-Y Financials

Financials (Next Earnings Date: 2016-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

MNTA Guru Trades in Q2 2015

Paul Tudor Jones 15,932 sh (New)
Jim Simons 466,851 sh (+99.13%)
PRIMECAP Management 2,700,900 sh (+0.22%)
Joel Greenblatt Sold Out
Steven Cohen Sold Out
» More
Q3 2015

MNTA Guru Trades in Q3 2015

Joel Greenblatt 29,352 sh (New)
Paul Tudor Jones 19,347 sh (+21.43%)
PRIMECAP Management 2,700,900 sh (unchged)
Jim Simons 438,366 sh (-6.10%)
» More
Q4 2015

MNTA Guru Trades in Q4 2015

John Paulson 21,800 sh (New)
Jim Simons 550,586 sh (+25.60%)
PRIMECAP Management 2,738,900 sh (+1.41%)
Paul Tudor Jones Sold Out
Joel Greenblatt 29,242 sh (-0.37%)
» More
Q1 2016

MNTA Guru Trades in Q1 2016

Jim Simons 1,029,051 sh (+86.90%)
PRIMECAP Management 2,738,900 sh (unchged)
John Paulson Sold Out
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MNTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:ACET, NAS:SGYP, NAS:AMPH, NAS:SGNT, NAS:EGRX, OTCPK:KHTRF, NAS:HRTX, OTCPK:EVTCY, NAS:SCMP, NAS:SCLN, NAS:SUPN, NAS:LBIO, NYSE:LCI, NAS:DEPO, NAS:FLXN, NAS:ADMS, OTCPK:CVNZF, NAS:COLL, NAS:CPXX, NAS:DRRX » details
Traded in other countries:LZ1.Germany,
Momenta Pharmaceuticals Inc is a biotechnology company. It is engaged in developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune disease.

Momenta Pharmaceuticals Inc was incorporated in the state of Delaware in May 2001 under the name of Mimeon, Inc., later changed the name Momenta Pharmaceuticals, Inc. in September 2002. The Company is a biotechnology company operating in three product areas: Complex Generics, Biosimilars and Novel therapeutics. In Complex Generics product area, the Company develops generic versions of complex drugs that were approved by the United States Food and Drug Administration under New Drug Applications. Enoxaparin Sodium Injection is the Company's first product to receive marketing approval under ANDA. The second complex generic product candidate, M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a complex drug consisting of a synthetic mixture of polypeptide chains. In Biosimilars product area, the Company is seeking to develop biosimilar versions of biologic medicines that were approved by the FDA under Biologics License Applications. Biologics are complex mixtures, and the Company unlocks their structural subtleties using an approach that is similar to the one it uses in the development of complex generics. Novel Drugs program uses the established characterization and process engineering capabilities from complex generics and biosimilars programs with a focus on polysaccharides and therapeutic proteins. Momenta were originally founded to develop novel drugs and it remains the long term goal for the Company. As with the complex generics and biosimilars the Company's platform gives a detailed understanding of the complex structures of novel product candidates, their associated manufacturing processes and controls, and the targeted biologic systems. The Company license or own a patent portfolio of over 100 patent families, each of which includes United States patent applications and/or issued patents as well as foreign counterparts. The Company relies on contract manufacturers since it does not own facilities for manufacturing any products.

Ratios

vs
industry
vs
history
P/B 2.22
MNTA's P/B is ranked higher than
60% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. MNTA: 2.22 )
Ranked among companies with meaningful P/B only.
MNTA' s P/B Range Over the Past 10 Years
Min: 1.34  Med: 3.08 Max: 13.69
Current: 2.22
1.34
13.69
P/S 7.17
MNTA's P/S is ranked lower than
76% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. MNTA: 7.17 )
Ranked among companies with meaningful P/S only.
MNTA' s P/S Range Over the Past 10 Years
Min: 1.83  Med: 16.63 Max: 55.5
Current: 7.17
1.83
55.5
EV-to-EBIT -5.03
MNTA's EV-to-EBIT is ranked lower than
99.99% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.71 vs. MNTA: -5.03 )
Ranked among companies with meaningful EV-to-EBIT only.
MNTA' s EV-to-EBIT Range Over the Past 10 Years
Min: -52.4  Med: -4.65 Max: 16.6
Current: -5.03
-52.4
16.6
EV-to-EBITDA -5.55
MNTA's EV-to-EBITDA is ranked lower than
99.99% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.97 vs. MNTA: -5.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNTA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -80.3  Med: -5.00 Max: 14.8
Current: -5.55
-80.3
14.8
Current Ratio 10.09
MNTA's Current Ratio is ranked higher than
91% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. MNTA: 10.09 )
Ranked among companies with meaningful Current Ratio only.
MNTA' s Current Ratio Range Over the Past 10 Years
Min: 4.39  Med: 11.52 Max: 28.87
Current: 10.09
4.39
28.87
Quick Ratio 10.09
MNTA's Quick Ratio is ranked higher than
92% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. MNTA: 10.09 )
Ranked among companies with meaningful Quick Ratio only.
MNTA' s Quick Ratio Range Over the Past 10 Years
Min: 4.39  Med: 11.52 Max: 28.87
Current: 10.09
4.39
28.87
Days Sales Outstanding 78.62
MNTA's Days Sales Outstanding is ranked lower than
54% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.90 vs. MNTA: 78.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNTA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.32  Med: 78.92 Max: 170.31
Current: 78.62
36.32
170.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.99
MNTA's Price/Net Cash is ranked higher than
79% of the 253 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.32 vs. MNTA: 2.99 )
Ranked among companies with meaningful Price/Net Cash only.
MNTA' s Price/Net Cash Range Over the Past 10 Years
Min: 2.03  Med: 4.18 Max: 14.33
Current: 2.99
2.03
14.33
Price/Net Current Asset Value 2.71
MNTA's Price/Net Current Asset Value is ranked higher than
81% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. MNTA: 2.71 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MNTA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.55  Med: 3.66 Max: 11.36
Current: 2.71
1.55
11.36
Price/Tangible Book 2.24
MNTA's Price/Tangible Book is ranked higher than
67% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.59 vs. MNTA: 2.24 )
Ranked among companies with meaningful Price/Tangible Book only.
MNTA' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.5  Med: 3.13 Max: 10.13
Current: 2.24
1.5
10.13
Price/Projected FCF 3.30
MNTA's Price/Projected FCF is ranked lower than
58% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. MNTA: 3.30 )
Ranked among companies with meaningful Price/Projected FCF only.
MNTA' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.77  Med: 3.53 Max: 8.31
Current: 3.3
1.77
8.31
Price/Median PS Value 0.43
MNTA's Price/Median PS Value is ranked higher than
94% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. MNTA: 0.43 )
Ranked among companies with meaningful Price/Median PS Value only.
MNTA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 0.93 Max: 2.76
Current: 0.43
0.11
2.76
Earnings Yield (Greenblatt) (%) -19.86
MNTA's Earnings Yield (Greenblatt) (%) is ranked lower than
88% of the 844 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. MNTA: -19.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNTA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -20.29  Med: 26.60 Max: 78.3
Current: -19.86
-20.29
78.3

More Statistics

Revenue (TTM) (Mil) $100.9
EPS (TTM) $ -1.27
Beta1.89
Short Percentage of Float7.80%
52-Week Range $7.86 - 23.62
Shares Outstanding (Mil)69.50

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 89 137 169
EPS ($) -1.41 -0.80 -0.98
EPS w/o NRI ($) -1.41 -0.80 -0.98
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MNTA

Headlines

Articles On GuruFocus.com
Very Low P/E Stocks Joel Greenblatt selected Dec 22 2011 
Momenta Pharmaceuticals Inc. (MNTA) SVP, CFO Richard P Shea sells 979 Shares Feb 24 2011 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 45,296 Shares Aug 05 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 7,800 Shares Mar 12 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 32,200 Shares Mar 10 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 1,413 Shares Mar 03 2010 

More From Other Websites
Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US :... Jul 29 2016
Momenta Pharmaceuticals Announces Date for Second Quarter 2016 Financial Results Conference Call and... Jul 21 2016
Zacks.com featured highlights: Momenta Pharmaceuticals, Acuity Brands, KEYW, Inteliquent and LATAM... Jul 14 2016
5 Best Stocks Forging Ahead on Earnings Acceleration Jul 13 2016
Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US :... Jun 27 2016
Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors Jun 23 2016
MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 23 2016
Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors Jun 23 2016
MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 22 2016
Visium Insider-Trading Scheme Brought Down by Mismarking Tip Jun 20 2016
Visium Hedge Fund Partner Charged in Insider Trading Case Jun 16 2016
UPDATE 3-Visium's Valvani charged with insider trading on FDA leaks Jun 15 2016
Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody Jun 09 2016
Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody Jun 09 2016
Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA® (adalimumab)... Jun 08 2016
Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA® (adalimumab)... Jun 08 2016
Coverage initiated on Momenta Pharma by Goldman Jun 06 2016
Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in... Jun 04 2016
Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in... Jun 04 2016
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 37th Annual Global Healthcare... May 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)